The effects of pathogen reduction technology on apheresis platelet concentrates stored in PAS.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: SIMTI servizi Country of Publication: Italy NLM ID: 101237479 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2385-2070 (Electronic) Linking ISSN: 17232007 NLM ISO Abbreviation: Blood Transfus Subsets: MEDLINE
    • Publication Information:
      Original Publication: Milano : SIMTI servizi
    • Subject Terms:
      Blood Preservation*/methods ; Blood Platelets*/metabolism ; Blood Platelets*/cytology ; Plateletpheresis*/methods; Humans ; Female ; Male ; Thrombelastography ; Platelet Transfusion/methods
    • Abstract:
      Background: The impact of pathogen reduction technology (PRT) such as Mirasol, and the effect of platelet additive solutions (PAS) on the activity and hemostatic profile of transfused apheresis platelets remain largely unknown. The aim of this study was to assess the in vitro hemostatic and metabolic profile of Mirasol treated platelets in PAS during a 7-day storage period.
      Material and Methods: Ten split bags containing apheresis platelets stored in PAS were split into two groups; control platelets (No.=10 units) and PRT-treated platelets (No.=10 units). In vitro evaluation of the platelet components was performed on the 1 st , 3 rd , 5 th , and 7 th days of the storage period. Several metabolic parameters including pH, glucose, and lactate levels were evaluated, while assessment of their hemostatic capacity was performed using light transmission aggregometry (LTA) and viscoelastic studies such as rotational thromboelastometry (ROTEM) and thromboelastography (TEG). Last, Annexin V levels were measured though flow cytometry for evaluation of platelet activation.
      Results: Clot strength, as reflected by the maximum clot firmness (MCF) and the maximum amplitude (MA) parameters of the viscoelastic studies was significantly decreased in the PRT-treated platelets compared to the control platelets (p<0.05). Clot strength based on MCF and MA values was also found to be decreasing over storage time in PRT-treated platelets (p<0.001), while this was not evident in control platelets. Moreover, the comparison between pH, glucose, and lactate levels were indicative of increased metabolic activity in PRT-treated platelets compared to control platelets (p<0.001). Last, Annexin-V was significantly higher in PRT-treated platelets compared to control platelets on the 7 th day of the storage period (p<0.001).
      Discussion: The results of this study indicate that increased PSL induced by PRT treatment leads to a decreased in vitro platelet hemostatic efficacy and increased metabolic activity. However, the clinical impact of these alterations needs further investigation.
    • References:
      Vox Sang. 2020 Aug;115(6):495-501. (PMID: 32311760)
      Transfusion. 2008 Aug;48(8):1685-92. (PMID: 18513255)
      Transfusion. 2016 Dec;56(12):2948-2952. (PMID: 27805261)
      Transfus Apher Sci. 2009 Oct;41(2):97-104. (PMID: 19699153)
      Transfusion. 2013 Aug;53(8):1780-7. (PMID: 23216254)
      Clin Lab Haematol. 2005 Apr;27(2):81-90. (PMID: 15784122)
      Curr Protoc Immunol. 2018 Feb 21;120:5.1.1-5.1.11. (PMID: 29512141)
      Adv Clin Exp Med. 2018 Jun;27(6):765-772. (PMID: 29877637)
      Blood Rev. 2014 Nov;28(6):235-41. (PMID: 25192602)
      Transfusion. 1994 Sep;34(9):779-83. (PMID: 8091467)
      Blood Transfus. 2022 May;20(3):223-234. (PMID: 34059193)
      Transfusion. 2010 Oct;50(10):2210-9. (PMID: 20456708)
      Semin Thromb Hemost. 2023 Jul;49(5):523-541. (PMID: 36252605)
      Transfusion. 2009 Nov;49(11):2311-8. (PMID: 19624608)
      PLoS One. 2020 May 29;15(5):e0233947. (PMID: 32470046)
      Transfusion. 2012 May;52(5):983-94. (PMID: 22014032)
      Transfus Med. 2016 Oct;26(5):339-342. (PMID: 27273164)
      Thromb Res. 2008;123(1):100-7. (PMID: 18430462)
      Blood Transfus. 2010 Jul;8(3):186-92. (PMID: 20671879)
      Blood Transfus. 2020 Jul;18(4):280-289. (PMID: 32530405)
      Vox Sang. 2011 Oct;101(3):208-14. (PMID: 21492184)
      Transfus Apher Sci. 2006 Aug;35(1):5-17. (PMID: 16935562)
      Transfusion. 2019 Dec;59(12):3783-3793. (PMID: 31642072)
      Vox Sang. 2009 Oct;97(3):234-9. (PMID: 19790298)
      Thromb Haemost. 2000 Sep;84(3):484-91. (PMID: 11019976)
      Transfus Apher Sci. 2013 Oct;49(2):285-90. (PMID: 23820429)
      Transfus Med Rev. 2019 Jan;33(1):29-34. (PMID: 30021699)
      Transfusion. 2011 Feb;51(2):344-56. (PMID: 20723169)
      Vox Sang. 2004 Jul;87 Suppl1:98-103. (PMID: 15200616)
      J Clin Invest. 1971 Feb;50(2):370-7. (PMID: 5540174)
      Transfus Apher Sci. 2008 Aug;39(1):75-82. (PMID: 18602343)
      Transfusion. 1988 Mar-Apr;28(2):123-6. (PMID: 3354039)
      Transfusion. 2006 Feb;46(2):204-12. (PMID: 16441596)
      Transfusion. 2017 Mar;57(3pt2):779-789. (PMID: 28164306)
      Vox Sang. 2016 Oct;111(3):247-256. (PMID: 27184018)
      Thromb Haemost. 1992 Nov 10;68(5):595-9. (PMID: 1455407)
      Transfusion. 2022 Jan;62(1):227-246. (PMID: 34870335)
    • Publication Date:
      Date Created: 20240205 Date Completed: 20240911 Latest Revision: 20240914
    • Publication Date:
      20240914
    • Accession Number:
      PMC11390611
    • Accession Number:
      10.2450/BloodTransfus.600
    • Accession Number:
      38315533